Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Dr Manish Saxena

Manish

Clinical Co-Director, William Harvey Clinical Research Centre and Deputy Director Research, Barts Health NHS Trust and QMUL

Centre: Clinical Pharmacology and Precision Medicine, Clinical Research Centre

Email: m.saxena@qmul.ac.uk
Telephone: +44(0) 20 7882 3856
Twitter: @DrManishNSaxena

Profile

Dr Saxena completed MBBS in 1996 and has been practising medicine for over 25 years. He completed a Master’s degree in Health Care Research and Clinical Drug Development with distinction from Queen Mary University of London. He is Deputy Director for Research for Barts Health NHS Trust/QMUL and Clinical Co-Director at the William Harvey Clinical Research Centre. He works at Barts Hypertension Clinic as a European Accredited specialist in hypertension. Dr Saxena has worked with the Health Research Authority as an expert member for over 12 years and has been chair of the National Research ethics committee for over 7 years. He is part of the National Institute for Health and Care Research (NIHR) leadership group as Speciality Research Lead for Diabetes for North Thames CRN. He is Academic Lead for Innovation and Commercial Partnerships for Barts Faculty of Medicine.

Research

Group members 

Armida Balawon, Ania Michalska, Francis Galera, Benildo Quiros, Aaron Jairo Oblena, Arooj Ayub, Brenda Roberts, Rizwana Ayub

Summary 

Dr Saxena is a cardiovascular (CV) physician passionate about developing novel therapies for CV prevention and treatment. As UK Chief Investigator and Barts lead, he leads on several studies in high-risk patients with dyslipidaemia (with second generation PCSK9i such as Inclisiran and oral PCSK9i, Bempedoic Acid, CETP modulators); in T2DM and CHF (SGLT2i, GLP-1, Aldose reductase inhibitors). He runs studies in Hypertension pioneering pharmacotherapy (SiRNA) and novel device therapies such as Renal Denervation, Carotid sinus modulation and Arterio-venous coupler besides collaborating on novel BP monitoring technologies such as Life light using remote PPG technology. He also works with patients with autonomic dysfunction and has run studies in patients with neurogenic orthostatic hypotension. His work also includes studies in other CV therapeutics involving anti-platelets, new oral anti-coagulants, dementia prevention and treatment.

Memberships and awards

  • Member European Society of HTN
  • Member European Society of Cardiology
  • Member Joint British and Irish Hypertension Society

Publications

  • Zappe D, Saxena M, Desai A et al. (2024). Abstract 4138847: Home Blood Pressure Reductions With Zilebesiran In Patients With Mild-To-Moderate Hypertension Are Consistent With Ambulatory And Office Blood Pressure Reductions In The KARDIA-1 Study. nameOfConference


    QMRO: qmroHref
  • Collier D, Taylor M, Godec T et al. (2024). Do more with less? Impact of personalized very low doses of amlodipine in the PERSONAL-CovidBP trial. nameOfConference


    QMRO: qmroHref
  • Saxena M, Aswad A, Badariene J et al. (2024). Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive. nameOfConference


    QMRO: qmroHref
  • Bloch MJ, Kirtane AJ, Azizi M et al. (2024). 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. nameOfConference


  • Greene SJ, Böhm M, Bozkurt B et al. (2024). Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry. nameOfConference


  • Unverdorben M, Colonna P, Jin J et al. (2024). Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program. nameOfConference


    QMRO: qmroHref
  • Saxena M (2024). Vaccines against angiotensin receptors as a potential treatment for hypertension. nameOfConference


  • Colonna P, Souza J, Saxena M et al. (2024). Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme. nameOfConference


  • Saxena M, Aswad A, Badariene J et al. (2024). ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY. nameOfConference


  • Hall CV, Twelves JL, Saxena M et al. (2024). Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial. nameOfConference


  • Kandzari DE, Weber MA, Pathak A et al. (2024). Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. nameOfConference


  • SAXENA M, Desai AS, Azizi M et al. (2024). CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION. nameOfConference


  • Bakris GL, Saxena M, Gupta A et al. (2024). RNA Interference With Zilebesiran for Mild to Moderate Hypertension. nameOfConference


  • Magavern EF, Kapil V, Saxena M et al. (2024). Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. nameOfConference


  • Collier DJ, Taylor M, Godec T et al. (2024). Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial). nameOfConference


  • Bertog SC, Sharma A, Hering D et al. (2023). Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter. nameOfConference


    QMRO: qmroHref
  • Saxena M, Lobo MD (2023). What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?. nameOfConference


    QMRO: qmroHref
  • von Heymann C, Unverdorben M, Colonna P et al. (publicationYear). Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study. nameOfConference


    QMRO: qmroHref
  • Florescu S, Stanciu D, Zaharia M et al. (2023). Intravenous Vitamin C for Patients Hospitalized With COVID-19. nameOfConference


  • Azizi M, Sharp ASP, Fisher NDL et al. (2024). Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program. nameOfConference


  • Azizi M, Saxena M, Wang Y et al. (2023). TCT-398 Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: 6-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial. nameOfConference


    QMRO: qmroHref
  • Santamaria A, Chen C, Colonna P et al. (2023). Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE. nameOfConference


    QMRO: qmroHref
  • Lobo MD, Rull G, Saxena M et al. (2023). Selecting patients for interventional procedures to treat hypertension. nameOfConference


  • Pathak A, Rudolph UM, Saxena M et al. (2023). Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.. nameOfConference


    QMRO: qmroHref
  • Chen C, Saxena M, von Heymann C et al. (publicationYear). Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database. nameOfConference


    QMRO: qmroHref
  • Kirtane AJ, Sharp ASP, Mahfoud F et al. (2023). Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. nameOfConference


    QMRO: qmroHref
  • Florescu S, Stanciu D, Zaharia M et al. (2023). Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19. nameOfConference


  • Azizi M, Saxena M, Wang Y et al. (2023). Endovascular Ultrasound Renal Denervation to Treat Hypertension. nameOfConference


  • Wiffen L, Brown T, Maczka AB et al. (publicationYear). Measurement of Vital Signs by Lifelight Software in Comparison to Standard of Care Multisite Development (VISION-MD): Protocol for an Observational Study. nameOfConference


    QMRO: qmroHref
  • Florescu S, Stanciu D, Zaharia M et al. (2023). Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. nameOfConference


  • Azizi M, Mahfoud F, Weber MA et al. (2022). Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation. nameOfConference


  • Heiden E, Jones T, Maczka AB et al. (publicationYear). Measurement of Vital Signs Using Lifelight Remote Photoplethysmography: Results of the VISION-D and VISION-V Observational Studies. nameOfConference


    QMRO: qmroHref
  • Rader F, Kirtane AJ, Wang Y et al. (publicationYear). Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.. nameOfConference


    QMRO: qmroHref
  • Bloch M, Kirtane A, Mahfoud F et al. (2022). TCT-212 Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial. nameOfConference


    QMRO: qmroHref
  • Saxena M, Von Heymann C, Santamaria A et al. (2022). Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program. nameOfConference


    QMRO: qmroHref
  • Florescu S, Stanciu D, Zaharia M et al. (2022). Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. nameOfConference


    QMRO: qmroHref
  • Taylor M, Godec T, Shiel J et al. (2022). WHOSE DOSE IS IT ANYWAY? INDIVIDUAL PATIENT DOSE-RESPONSE CURVES FROM THE REMOTE-CARE PERSONAL-COVIDBP TRIAL. nameOfConference


    QMRO: qmroHref
  • Collier D, Taylor M, Godec T et al. (2022). Personalized electronic record supported optimisation when alone for patients with hypertension- pilot study for remote medical management of hypertension during the Covid-19 pandemic (personal covidBP). nameOfConference

    DOI: doi

  • Bloch M, Kirtane A, Mahfoud F et al. (2022). Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Unverdorben M, von Heymann C, Santamaria A et al. (2022). Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program. nameOfConference


    QMRO: qmroHref
  • von Heymann C, Unverdorben M, Colonna P et al. (2021). Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. nameOfConference


    QMRO: qmroHref
  • Linschoten M, Uijl A, Schut A et al. (2022). Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries. nameOfConference


    QMRO: qmroHref
  • Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF et al. (2021). Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.. nameOfConference


  • Rader F, Kirtane A, Wang Y et al. (2021). TCT-369 Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial. nameOfConference


    QMRO: qmroHref
  • Fisher NDL, Kirtane AJ, Daemen J et al. (2022). Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. nameOfConference


    QMRO: qmroHref
  • Vanassche T, Colonna P, Santamaria A et al. (2021). Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study. nameOfConference


    QMRO: qmroHref
  • Unverdorben M, Colonna P, Von Heymann C et al. (2021). Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study. nameOfConference


    QMRO: qmroHref
  • Saxena M, Schmieder RE, Kirtane AJ et al. (2022). Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. nameOfConference


  • Azizi M, Sanghvi K, Saxena M et al. (2021). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. nameOfConference


    QMRO: qmroHref
  • Saxena M, Kermali M, Balawon A et al. (2021). COLLATERAL BENEFITS OF PARTICIPATION IN CLINICAL RESEARCH: INSIGHTS FROM A RESISTANT HYPERTENSION TRIAL SCREEN OUT POPULATION. nameOfConference


    QMRO: qmroHref
  • Unverdorben M, von Heymann C, Santamaria A et al. (2021). Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. nameOfConference


    QMRO: qmroHref
  • Rader F, Kirtane A, Wang Y et al. (2021). Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Maniero C, Julu P, Shah M et al. (2021). Dysregulation of central respiratory modulation of cardiac vagal tone is a novel, early sign of dysautonomia in patients with α-synucleinopathies. nameOfConference

    DOI: doi

  • Gosse P, Cremer A, Kirtane AJ et al. (2021). Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. nameOfConference


    QMRO: qmroHref
  • Azizi M, Daemen J, Lobo MD et al. (2020). 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. nameOfConference


    QMRO: qmroHref
  • Unverdorben M, von Heymann C, Santamaria A et al. (2020). Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. nameOfConference


    QMRO: qmroHref
  • Feyz L, Wang Y, Pathak A et al. (2020). Using social media to recruit study participants for a randomized trial for hypertension. nameOfConference


    QMRO: qmroHref
  • Santamaria A, Colonna P, von Heymann C et al. (2020). Periprocedural Interruption of Edoxaban in Real World Setting: Results from the Emit AF/VTE Study. nameOfConference


    QMRO: qmroHref
  • Bertog S, Sharma A, Mahfoud F et al. (2021). Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter. nameOfConference


    QMRO: qmroHref
  • Colonna P, von Heymann C, Santamaria A et al. (2020). Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study. nameOfConference


    QMRO: qmroHref
  • Saxena M, Kermali M, Balawon A et al. (2020). Collateral benefits of participation in clinical research: insights from a resistant hypertension trial screen out population. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Lobo MD, Sharp ASP, Kapil V et al. (2019). Joint UK societies’ 2019 consensus statement on renal denervation. nameOfConference


  • Azizi M, Schmieder RE, Mahfoud F et al. (2019). Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. nameOfConference


  • Azizi M, Schmieder R, Mahfoud F et al. (2019). TREATMENT-BLINDED MEDICATION TITRATION FOR HYPERTENSION CONTROL FOLLOWING RANDOMIZATION TO ENDOVASCULAR ULTRASOUND RENAL DENERVATION OR A SHAM PROCEDURE. nameOfConference


    QMRO: qmroHref
  • McGuire DK, Alexander JH, Johansen OE et al. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. nameOfConference


    QMRO: qmroHref
  • Rosenstock J, Perkovic V, Johansen OE et al. (2019). Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.. nameOfConference


    QMRO: qmroHref
  • Sharp ASP, Saxena M, Lobo MD (2018). Renal artery sympathetic denervation: Back on track!. nameOfConference


    QMRO: qmroHref
  • Saxena M, Shour T, Shah M et al. (2018). Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success.. nameOfConference


  • Williams B, MacDonald TM, Morant SV et al. (2018). Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.. nameOfConference


  • Saxena M, Sobotka P, Balmforth P et al. (2018). IMMEDIATE, SIGNIFICANT DECLINE IN CENTRAL AND PERIPHERAL BLOOD PRESSURE WITH CENTRAL ARTERIAL VENOUS ANASTOMOSIS. nameOfConference


    QMRO: qmroHref
  • BROWN MJ (2018). Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study. nameOfConference


  • Azizi M, Schmieder RE, Mahfoud F et al. (2018). Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. nameOfConference


    QMRO: qmroHref
  • Mukhtar O, Cheriyan J, Cockcroft JR et al. (2018). A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. nameOfConference


    QMRO: qmroHref
  • Schmieder RE, Ott C, Toennes SW et al. (2018). Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV. nameOfConference


    QMRO: qmroHref
  • MacDonald TM, Williams B, Webb DJ et al. (2017). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.. nameOfConference


  • Lobo MD, Ott C, Sobotka PA et al. (2017). Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension. nameOfConference


    QMRO: qmroHref
  • Schmieder RE, Ott C, Toennes S et al. (2017). [LB.01.02] PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV. nameOfConference


    QMRO: qmroHref
  • Saxena M, Shour T, Shah M et al. (2017). [LB.03.06] ATTENUATION OF SPLANCHNIC AUTOTRANSFUSION FOLLOWING NON-INVASIVE ULTRASOUND RENAL DENERVATION. nameOfConference


  • Ormiston J, Neuzil P, O’brien B et al. (2017). [PP.15.25] REDO RENAL DENERVATION WITH NON-INVASIVE THERAPEUTIC ULTRASOUND. nameOfConference


    QMRO: qmroHref
  • Lobo M, Montarello J, Saxena M et al. (2017). [PP.15.26] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS. nameOfConference


    QMRO: qmroHref
  • SAXENA M, Shour T, Sobotka P et al. (2017). [PP.24.26] ANTIHYPERTENSIVE EFFECTS OF A CENTRAL ARTERIOVENOUS ANASTOMOSIS ARE MEDIATED THROUGH PROFOUND REDUCTION IN SYSTEMIC VASCULAR RESISTANCE. nameOfConference


  • Saxena M, Shour T, Shah M et al. (2017). Attenuation of splanchnic autotransfusion following non-invasive ultrasound renal denervation: a novel marker of procedural success. nameOfConference

    DOI: doi

  • Ott C, Lobo MD, Sobotka PA et al. (2016). Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension.. nameOfConference


  • Floyd CN, Adeel MY, Wolff CB et al. (2016). First-in-man treatment of severe blood pressure variability with baroreflex activation therapy. nameOfConference


  • Lobo MD, Montarello J, Saxena M et al. (2016). [OP.4C.04] SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION. nameOfConference


    QMRO: qmroHref
  • Lobo MD, Adeel MY, Wolff CB et al. (2016). [OP.8D.02] FIRST IN MAN TREATMENT OF SEVERE BP VARIABILITY WITH BAROREFLEX ACTIVATION THERAPY.. nameOfConference


  • Lobo M, Saxena M, Sobotka PA et al. (2016). [OP.LB.02.04] CENTRAL ILIAC ARTERIOVENOUS ANASTOMOSIS FOR UNCONTROLLED HYPERTENSION. nameOfConference


    QMRO: qmroHref
  • Lobo MD, Montarello J, Saxena M et al. (2016). [PP.26.11] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS. nameOfConference


    QMRO: qmroHref
  • Wolff C, Julu PO, Collier DJ et al. (2016). [PP.38.09] EFFECTS OF MILD DYNAMIC EXERCISE ON CIRCULATORY AND AUTONOMIC FUNCTION IN HEALTHY VOLUNTEERS. nameOfConference


  • Saxena M, Sobotka PA, Hamshere SM et al. (2016). Antihypertensive effects of a central arteriovenous anastomosis are mediated through profound reduction in systemic vascular resistance. nameOfConference


  • Ng FL, Saxena M, Mahfoud F et al. (2016). Device-based Therapy for Hypertension.. nameOfConference


  • De Jager RL, Sanders MF, Bots ML et al. (2016). Renal denervation in hypertensive patients not on blood pressure lowering drugs. nameOfConference


    QMRO: qmroHref
  • Saxena M, Antoniou S, Hamedi N et al. (2016). Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm. nameOfConference


    QMRO: qmroHref
  • Burchell AE, Chan K, Ratcliffe LEK et al. (2016). Controversies Surrounding Renal Denervation: Lessons Learned From Real‐World Experience in Two United Kingdom Centers. nameOfConference


    QMRO: qmroHref
  • Antoniou S, Saxena M, Hamedi N et al. (2016). Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm. nameOfConference


  • Wolff CB, Collier DJ, Shah M et al. (2016). A Discussion on the Regulation of Blood Flow and Pressure. nameOfConference


    QMRO: qmroHref
  • Antoniou S, Saxena M, Hamedi N et al. (2016). Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm. nameOfConference


    QMRO: qmroHref
  • Lobo M, Montarello J, Saxena M et al. (2015). TCT-771 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study. nameOfConference


    QMRO: qmroHref
  • Worthley SG, Montarello J, Saxena M et al. (2015). TCT-774 Safety and Performance of the EnligHTN™ Renal Denervation System in Patients with Drug-resistant Hypertension: Pooled analyses from the EnligHTN I, II and III trials. nameOfConference


    QMRO: qmroHref
  • Lobo M, Montarello J, Saxena M et al. (2015). TCT-85 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Severe Uncontrolled Hypertension: 12 Month Results from the EnligHTN II Study. nameOfConference


    QMRO: qmroHref
  • Kapil V, Sobotka PA, Saxena M et al. (2015). Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation. nameOfConference


  • Lobo M, Saxena M, Jain AJ et al. (2015). 4A.09. nameOfConference


    QMRO: qmroHref
  • Saxena M, Collier D, Jain A et al. (2015). 8C.09. nameOfConference


    QMRO: qmroHref
  • Antoniou S, Saxena M, Hamedi N et al. (2015). PP.21.35. nameOfConference


    QMRO: qmroHref
  • Worthley S, Montarello J, Saxena M et al. (2015). PP.26.05. nameOfConference


    QMRO: qmroHref
  • Lobo M, Saxena M, Jain A et al. (2015). PP.26.22. nameOfConference


    QMRO: qmroHref
  • Lobo M, Saxena M, Jain A et al. (2015). PP.26.23. nameOfConference


    QMRO: qmroHref
  • Antoniou S, Hamedi N, Lidder S et al. (2015). CP-081 Management of uncontrolled blood pressure in patients with multiple drug intolerance referred to a specialist hypertension clinic. nameOfConference


    QMRO: qmroHref
  • Saxena M, Collier D, Jain A et al. (2015). A central iliac arteriovenous anastomosis results in durable and substantial blood pressure reduction in a woman with uncontrolled hypertension and multiple antihypertensive drug intolerances. nameOfConference

    DOI: doi

  • Burchell AE, Chan K, Hart EC et al. (2015). Challenges facing renal denervation: insight from real world experience at two UK centres. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Lobo M, Saxena M, Jain A et al. (2015). SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH MODERATE UNCONTROLLED HYPERTENSION: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Lobo M, Saxena M, Jain A et al. (2015). SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Worthley S, Montarello J, Saxena M et al. (2015). SAFETY AND PERFORMANCE OF THE ENLIGHTN™ RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION: POOLED ANALYSES FROM THE ENLIGHTN I, II AND III TRIALS. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Lobo MD, Montarello J, Saxena M et al. (2015). Safety and performance of the EnligHTN renal denervation system in patients with severe uncontrolled hypertension: 12 month results from the EnligHTN II Study. nameOfConference

    DOI: doi

  • Saxena M, Antoniou S, Hamedi N et al. (2014). Anti-hypertensive medicine intolerance - an overlooked and important cause of failed compliance. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Saxena M, Jain A, Mathur A et al. (2014). Early reduction in blood pressure and heart rate variability following multielectrode radio-frequency renal denervation in medicines intolerant patients. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Burchell A, Chan K, Ratcliffe L et al. (2014). Highly variable response to renal denervation for resistant hypertension - real world experience from 2 UK centres. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Antoniou S, Hamedi N, Choudhury R et al. (2014). Management of uncontrolled blood pressure in patients referred to a specialist hypertension clinic with multiple medicines intolerance. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Saxena M, Collier D, Caulfield M et al. (2012). Patients with resistant hypertension warrant a trial of salt restriction before and after renal denervation (RD). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Chan K, Ng FL, Saxena M et al. (2012). Renal denervation in resistant hypertension-a prospective case series. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier DJ, Robson J, Scott R et al. (2010). HiLo: a health services intervention study: methods and interim results on the first 2000 patients at 1 year. nameOfConference

    DOI: doi

    QMRO: qmroHref

Sponsors

Collaborators

  • Prof Anoop Chauhan, MBE, Director Research & Innovation, Portsmouth Hospitals NHS Trust
  • Prof Melvin Lobo, Director Barts BP Services
  • Prof Feng He, Prof of Global Health Research, Wolfson Institute
  • Dr David Collier, Deputy Director, Barts CTU
  • Antonio Sotiris, Chief Pharmacist Barts Hospital
  • Oxford Clinical Trials Unit
  • Blood Pressure UK

News

June 2022

May 2022

April 2022

December 2021

June 2021

November 2010

Back to top